Savient Pharmaceuticals Inc Revenue Growth Rates (SVNT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Savient Pharmaceuticals Inc  (SVNT)
 

SVNT's Revenue Growth by Quarter and Year

Savient Pharmaceuticals Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SVNT Revenue (in millions $) FY 2013 FY 2012 FY 2011 FY 2010
4th Quarter December -
3rd Quarter September 6.57
2nd Quarter June 6.66
1st Quarter March 0.00
FY 13.23





SVNT Revenue third quarter 2013 Y/Y Growth Comment
Savient Pharmaceuticals Inc reported Revenue improvement of 33.48% year on year in the third quarter 2013, to $ 6.57 millions, this is lower than Savient Pharmaceuticals Inc's recent average Revenue surge of 118.07%.

Looking into third quarter 2013 results within Biotechnology & Pharmaceuticals industry 2 other companies have achieved higher Revenue growth. While Savient Pharmaceuticals Inc' s Revenue rise of 33.48% ranks overall at the positon no. 72 in the third quarter 2013.


SVNT Revenue ( Y/Y Growth %) 2013
 2012 2011 2010
4th Quarter December - 33.42 % 286.46 % 190.91 %
3rd Quarter September 33.48 % 90.7 % 160.61 % 45.59 %
2nd Quarter June 43.84 % 133.84 % 100 % -
1st Quarter March - 173.64 % 18.35 % -
FY   - 88.6 % 137.22 % -

Financial Statements
Savient Pharmaceuticals Inc's third quarter 2013 Revenue $ 6.57 millions SVNT's Income Statement
Savient Pharmaceuticals Inc's third quarter 2012 Revenue $ 4.92 millions Quarterly SVNT's Income Statement


SVNT Revenue (Quarter on Quarter Growth %)

 2013
 2012 2011 2010
4th Quarter December - 0.61 % 43.8 % -3.03 %
3rd Quarter September -1.4 % 6.26 % 30.3 % 0 %
2nd Quarter June - 31.16 % 53.49 % -9.17 %
1st Quarter March - -4.85 % 34.38 % 230.3 %
FY (Year on Year)   - 88.6 % 137.22 % -


Back to SVNT Growth rate Comparisons >> Back to SVNT Growth rate Comparisons >>


Revenue third quarter 2013 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #3
Healthcare Sector #20
Overall #72

Revenue Y/Y Growth Statistics
High Average Low
179.5 % 118.07 % 46.36 %
(Mar 31 2012)   (Jun 30 2013)
Revenue third quarter 2013 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #3
Healthcare Sector #20
Overall #72
Revenue Y/Y Growth Statistics
High Average Low
179.5 % 118.07 % 46.36 %
(Mar 31 2012)   (Jun 30 2013)

Revenue by Quarter for the Fiscal Years 2010, 2011, 2012, 2013

Savient Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
53.8 % 2.1 % -100 %
(Jun 30 2011)  


SVNT's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2013 Savient Pharmaceuticals Inc disclosed decrease in Revenue from the second quarter by -1.4% to $ 6.57 millions, from $ 6.66 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2013 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Savient Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 2703.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #35
Healthcare Sector #311
Overall #2703
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #35
Healthcare Sector #311
Overall #2703
Revenue Q/Q Growth Statistics
High Average Low
53.8 % 2.1 % -100 %
(Jun 30 2011)  


SVNT's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2013 Savient Pharmaceuticals Inc disclosed decrease in Revenue from the second quarter by -1.4% to $ 6.57 millions, from $ 6.66 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2013 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Savient Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 2703.


Savient Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2013)		 12 Months Ending
(Jun 30 2013)		 12 Months Ending
(Mar 31 2013)		 12 Months Ending
(Dec 31 2012)		 12 Months Ending
(Sep 30 2012)
Cumulative Revenue 12 Months Ending $ 0.00 $ 21.15 $ 0.00 $ 18.02 $ 16.79
Y / Y Revenue Growth (TTM) - 46.36 % - 88.43 % 146.31 %
Year on Year Revenue Growth Overall Ranking # 72 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) - 17.36 % - 7.37 % 16.16 %
Seq. Revenue Growth (TTM) Overall Ranking # 115 # 114 # 0 # 0 # 0


Cumulative Revenue growth Comment
Savient Pharmaceuticals Inc realized trailing twelve months of $ 0 millions, in the Sep 30 2013, compare to Revenue of $ 17 millions a year ago.

Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 72.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 1
Healthcare Sector # 20
Overall # 72

Revenue TTM Y/Y Growth Statistics
High Average Low
179.5 %
 118.07 %
46.36 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 14
S&P 500 # 115
Cumulative Revenue growth Comment
Savient Pharmaceuticals Inc realized trailing twelve months of $ 0 millions, in the Sep 30 2013, compare to Revenue of $ 17 millions a year ago.

Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 72.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 1
Healthcare Sector # 20
Overall # 72

Revenue TTM Y/Y Growth Statistics
High Average Low
179.5 %
118.07 %
46.36 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 14
S&P 500 # 115




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SVNT's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Sep 30 2013 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2013
Geovax Labs Inc 57.40%$ 57.400 millions
Strata Skin Sciences Inc55.81%$ 55.810 millions
Davita Inc 52.81%$ 52.809 millions
Gt Biopharma Inc 52.50%$ 52.500 millions
Myriad Genetics Inc 51.73%$ 51.732 millions
Achieve Life Sciences Inc 50.11%$ 50.107 millions
Axogen inc 49.30%$ 49.303 millions
Seer Inc 48.10%$ 48.104 millions
Vycor Medical Inc 46.12%$ 46.115 millions
Cytosorbents Corporation45.49%$ 45.486 millions
Nutrastar International Inc.44.42%$ 44.418 millions
Bohai Pharmaceuticals Group, Inc.43.96%$ 43.963 millions
Standard Biotools Inc 43.07%$ 43.068 millions
Seagen Inc 42.42%$ 42.417 millions
Incyte Corporation40.72%$ 40.718 millions
International Stem Cell Corporation40.69%$ 40.691 millions
Regeneron Pharmaceuticals Inc 39.59%$ 39.594 millions
Nanostring Technologies Inc 39.01%$ 39.006 millions
Escalon Medical Corp 37.91%$ 37.915 millions
Vyant Bio Inc 37.22%$ 37.224 millions
Musclepharm Corporation36.45%$ 36.451 millions
Alexion Pharmaceuticals Inc 36.13%$ 36.129 millions
Chemocentryx Inc.34.93%$ 34.929 millions
Emergent Biosolutions Inc 33.80%$ 33.803 millions
Savient Pharmaceuticals Inc33.58%$ 33.584 millions
Vaso Corporation32.93%$ 32.926 millions
Jazz Pharmaceuticals Plc32.27%$ 32.274 millions
Biogen Inc 31.92%$ 31.917 millions
Sanara Medtech Inc 31.26%$ 31.260 millions
Cambrex Corp30.81%$ 30.809 millions


About Savient Pharmaceuticals Inc Revenue Growth Rates (SVNT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.